Aditxt Inc (ADTX)

$0.06 0.00 (-5.39%)
Market Cap 76,000.00
Revenue (ttm) 3,195.00
Net Income (ttm) -41.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 25,026,801
Avg Vol 2,562,743
Day's Range N/A - N/A
Shares Out 904,000.00
Stochastic %K 8%
Beta 1.08
Analysts Strong Buy
Price Target $61.00

Company Profile

Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 870 1200
Address:
2569 Wyandotte Street, Suite 101, Mountain View, United States
ChiRoj312
ChiRoj312 May. 15 at 10:38 PM
$ADTX
0 · Reply
Alchemy_Trader
Alchemy_Trader May. 15 at 10:27 PM
$ADTX hope they have solid plans to keep this over $1.00
0 · Reply
TwongStocks
TwongStocks May. 15 at 10:14 PM
After a fairly quiet week, Monday will open up with eight reverse splits. Seven on NASDAQ and one on the NYSE American. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Monday morning. I'll have to split this into two parts. PART 1 of 2 NYSE American: $MI 1 for 80. Will reduce outstanding Class A shares from approx 18.48m to approx 231k. NASDAQ: $ADTX 1 for 27. Will reduce outstanding shares from approx 13.77m to approx 510k. $EZRA 1 for 40. Will reduce outstanding shares from approx 22.23m to approx 556k. $FRGT 1 for 5. Will reduce outstanding shares from approx 2.86m to approx 572k.
0 · Reply
Adrennaline
Adrennaline May. 15 at 9:57 PM
$ADTX load the boat guys..monday gomna be great
0 · Reply
Adrennaline
Adrennaline May. 15 at 9:54 PM
$ADTX this will have a nice run
0 · Reply
Adrennaline
Adrennaline May. 15 at 9:54 PM
$ADTX added
0 · Reply
TheNewz
TheNewz May. 15 at 9:40 PM
$ADTX Added 📰
0 · Reply
Bull_shift
Bull_shift May. 15 at 9:22 PM
$ADTX classic rug
0 · Reply
Jagerx
Jagerx May. 15 at 9:05 PM
$ADTX
0 · Reply
TheNewz
TheNewz May. 15 at 8:57 PM
$ADTX Shorts covering prior to Monday 📰
0 · Reply
Latest News on ADTX
Aditxt announces 1-for-27 reverse stock split

2026-05-14T16:21:02.000Z - 1 day ago

Aditxt announces 1-for-27 reverse stock split

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

May 14, 2026, 8:15 AM EDT - 1 day ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

Aditxt announces publication featuring Ignite Proteomics subsidiary

2026-04-20T12:30:43.000Z - 25 days ago

Aditxt announces publication featuring Ignite Proteomics subsidiary

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

Apr 20, 2026, 8:15 AM EDT - 25 days ago

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

Aditxt files to sell 148.28M shares of common stock for holders

2026-04-13T10:11:46.000Z - 4 weeks ago

Aditxt files to sell 148.28M shares of common stock for holders

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

Mar 19, 2026, 8:15 AM EDT - 2 months ago

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

Aditxt acquires Ignite Proteomics in $36M transaction

2026-03-13T12:55:13.000Z - 2 months ago

Aditxt acquires Ignite Proteomics in $36M transaction

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

Mar 13, 2026, 8:15 AM EDT - 2 months ago

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

Aditxt to effect 1-for-8 reverse split of common stock

2026-03-05T14:03:50.000Z - 2 months ago

Aditxt to effect 1-for-8 reverse split of common stock

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

Mar 5, 2026, 8:30 AM EST - 2 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

3 Penny Stocks to Watch Now, 12/2/25

2025-12-02T16:19:00.000Z - 5 months ago

3 Penny Stocks to Watch Now, 12/2/25

BEAM KTTA

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

Nov 18, 2025, 8:00 AM EST - 6 months ago

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Aditxt begins enrollment in Mitomic Endometriosis Test study

2025-10-27T13:00:25.000Z - 7 months ago

Aditxt begins enrollment in Mitomic Endometriosis Test study

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Oct 27, 2025, 8:30 AM EDT - 7 months ago

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Evofem Announces Voting Results from Special Meeting of Stockholders

Oct 20, 2025, 4:19 PM EDT - 7 months ago

Evofem Announces Voting Results from Special Meeting of Stockholders

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Sep 11, 2025, 9:18 AM EDT - 8 months ago

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Sep 9, 2025, 9:28 AM EDT - 8 months ago

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Aug 25, 2025, 9:15 AM EDT - 9 months ago

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

Aug 21, 2025, 8:56 AM EDT - 9 months ago

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Aug 19, 2025, 9:39 AM EDT - 9 months ago

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aug 14, 2025, 8:46 AM EDT - 9 months ago

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Aug 11, 2025, 8:30 AM EDT - 9 months ago

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Aug 5, 2025, 8:46 AM EDT - 10 months ago

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Jul 29, 2025, 9:00 AM EDT - 10 months ago

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Jul 24, 2025, 8:15 AM EDT - 10 months ago

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Jul 22, 2025, 8:15 AM EDT - 10 months ago

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Jul 15, 2025, 9:12 AM EDT - 10 months ago

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Jul 7, 2025, 8:15 AM EDT - 11 months ago

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Jun 26, 2025, 8:15 AM EDT - 11 months ago

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Aditxt files to sell up to 50M shares of common stock for holders

2025-06-20T21:15:06.000Z - 11 months ago

Aditxt files to sell up to 50M shares of common stock for holders

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Jun 11, 2025, 8:14 AM EDT - 1 year ago

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Aditxt appoints Evofem CEO Saundra Pelletier to board

2025-06-09T12:20:54.000Z - 1 year ago

Aditxt appoints Evofem CEO Saundra Pelletier to board

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Jun 9, 2025, 8:15 AM EDT - 1 year ago

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Jun 5, 2025, 8:15 AM EDT - 1 year ago

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Aditxt announces termination of arrangement agreement with Appili Therapeutics

2025-05-19T12:11:08.000Z - 1 year ago

Aditxt announces termination of arrangement agreement with Appili Therapeutics

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

May 19, 2025, 8:00 AM EDT - 1 year ago

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

May 2, 2025, 9:00 AM EDT - 1 year ago

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Apr 17, 2025, 8:15 AM EDT - 1 year ago

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Apr 16, 2025, 8:15 AM EDT - 1 year ago

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Aditxt announces results from ADI-100 study

2025-04-14T12:27:42.000Z - 1 year ago

Aditxt announces results from ADI-100 study

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Apr 14, 2025, 8:15 AM EDT - 1 year ago

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Apr 11, 2025, 8:15 AM EDT - 1 year ago

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Apr 9, 2025, 8:15 AM EDT - 1 year ago

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Appili Therapeutics CEO to join Aditxt CEO for weekly update on April 4

2025-04-02T12:27:07.000Z - 1 year ago

Appili Therapeutics CEO to join Aditxt CEO for weekly update on April 4

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Apr 2, 2025, 8:15 AM EDT - 1 year ago

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Mar 28, 2025, 8:15 AM EDT - 1 year ago

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Mar 24, 2025, 8:15 AM EDT - 1 year ago

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Mar 17, 2025, 8:15 AM EDT - 1 year ago

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Mar 12, 2025, 4:15 PM EDT - 1 year ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Mar 6, 2025, 8:15 AM EST - 1 year ago

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Feb 21, 2025, 8:15 AM EST - 1 year ago

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Feb 13, 2025, 8:15 AM EST - 1 year ago

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Jan 13, 2025, 8:15 AM EST - 1 year ago

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Dec 12, 2024, 8:15 AM EST - 1 year ago

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Nov 14, 2024, 4:36 PM EST - 1 year ago

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Nov 8, 2024, 8:30 AM EST - 1 year ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Nov 7, 2024, 8:30 AM EST - 1 year ago

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Nov 6, 2024, 8:30 AM EST - 1 year ago

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Nov 6, 2024, 8:00 AM EST - 1 year ago

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

ChiRoj312
ChiRoj312 May. 15 at 10:38 PM
$ADTX
0 · Reply
Alchemy_Trader
Alchemy_Trader May. 15 at 10:27 PM
$ADTX hope they have solid plans to keep this over $1.00
0 · Reply
TwongStocks
TwongStocks May. 15 at 10:14 PM
After a fairly quiet week, Monday will open up with eight reverse splits. Seven on NASDAQ and one on the NYSE American. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Monday morning. I'll have to split this into two parts. PART 1 of 2 NYSE American: $MI 1 for 80. Will reduce outstanding Class A shares from approx 18.48m to approx 231k. NASDAQ: $ADTX 1 for 27. Will reduce outstanding shares from approx 13.77m to approx 510k. $EZRA 1 for 40. Will reduce outstanding shares from approx 22.23m to approx 556k. $FRGT 1 for 5. Will reduce outstanding shares from approx 2.86m to approx 572k.
0 · Reply
Adrennaline
Adrennaline May. 15 at 9:57 PM
$ADTX load the boat guys..monday gomna be great
0 · Reply
Adrennaline
Adrennaline May. 15 at 9:54 PM
$ADTX this will have a nice run
0 · Reply
Adrennaline
Adrennaline May. 15 at 9:54 PM
$ADTX added
0 · Reply
TheNewz
TheNewz May. 15 at 9:40 PM
$ADTX Added 📰
0 · Reply
Bull_shift
Bull_shift May. 15 at 9:22 PM
$ADTX classic rug
0 · Reply
Jagerx
Jagerx May. 15 at 9:05 PM
$ADTX
0 · Reply
TheNewz
TheNewz May. 15 at 8:57 PM
$ADTX Shorts covering prior to Monday 📰
0 · Reply
buttercup1007
buttercup1007 May. 15 at 8:53 PM
$ADTX
0 · Reply
AlertsAndNews
AlertsAndNews May. 15 at 8:51 PM
Gappers here in after hours trading $ARAY $ARTL $ZTG.X $SOPA $ADTX Cheers to a great week! Ill update over the weekend!
0 · Reply
GrimSignal
GrimSignal May. 15 at 8:48 PM
$ADTX what did i say ?
0 · Reply
BlackSoul
BlackSoul May. 15 at 8:47 PM
$ADTX there you go 50%+
0 · Reply
Aminovich87
Aminovich87 May. 15 at 8:34 PM
$ADTX Dilution machine
0 · Reply
PnD69
PnD69 May. 15 at 8:09 PM
$ADTX not one pump since January
0 · Reply
Trade_the_plan
Trade_the_plan May. 15 at 5:11 PM
$ADTX any time you see Sabby goin going. Sell and never buy
0 · Reply
BlackSoul
BlackSoul May. 15 at 4:15 PM
$ADTX careful for today last day to get out, unless you want in RS monday open PM, me personally i will go out EOD if nothing happens for 10-20% move
0 · Reply
ricky_lafleur
ricky_lafleur May. 15 at 3:05 PM
$ADTX the MULN is biojunk well done scamro
0 · Reply
exile0002
exile0002 May. 15 at 2:07 PM
$ADTX please delist this scam soon !!!!!
0 · Reply
jaetee66
jaetee66 May. 15 at 1:08 PM
$ADTX You paid too much for those. Trust me.
0 · Reply
jaetee66
jaetee66 May. 15 at 1:06 PM
$ADTX First a dime, next is a nickel, then a penny... Too bad this doesn't end with Scamro in front of a jury.
0 · Reply